TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 BA
Boeing
-- 178.110 PLTR
Palantir
-- 90.960 MU
Micron Technology
-- 94.720 
Update
$BriaCell Therapeutics (BCTX.US)$ BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
GlobeNewswire· 6 mins
GlobeNewswire· 6 mins
SABCS "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calculation is pending, as many patients remain alivePotential identification of biomarkers to predict responseFive poster presentations to feature increased presence of cancer fighting CD8+ "killer" T cell in metastatic breast cancer tumors, response in central nervous system (CNS) metastases and additional Bria-IMT clinical data from the Phase 2 trial of Bria-IMT + immune check point inhibitor in metastatic breast cancer Collaboration with the Medical College of Wisconsin will investigate use of Bria-IMT + CPI in any cancer patient with central nervous system (CNS) metastases
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment